Disease Markers / 2019 / Article / Tab 2

Research Article

miR-34b/c rs4938723 T>C Decreases Neuroblastoma Risk: A Replication Study in the Hunan Children

Table 2

Association between miR34b/c rs4938723 T>C polymorphism and clinical parameters.

VariablesCases/controlsOR (95% CI)AOR (95% CI)aa
TTTC/CC
No. (%)No. (%)

Age (month)
≤1842/36 (25.9)/(13.3)27/66 (16.7)/(24.4)0.35 (0.19-0.66)0.0010.35 (0.18-0.67)0.002
>1858/81 (35.8)/(30.0)35/87 (21.6)/(32.2)0.56 (0.34-0.94)0.0290.55 (0.32-0.94)0.027
Gender
Females49/52 (30.2)/(19.2)30/77 (18.5)/(28.5)0.41 (0.23-0.74)0.0030.45 (0.24-0.82)0.010
Males51/65 (31.5)/(24.1)32/76 (19.7)/(28.1)0.54 (0.31-0.93)0.0270.52 (0.29-0.90)0.020
Sites of origin
Adrenal gland17/117 (10.5)/(43.3)14/153 (8.64)/(56.7)0.63 (0.30-1.33)0.2250.65 (0.31-1.38)0.265
Retroperitoneal55/117 (33.9)/(43.3)23/153 (14.2)/(56.7)0.32 (0.19-0.55)<0.00010.35 (0.20-0.60)0.0002
Mediastinum16/117 (9.87)/(43.3)20/153 (12.3)/(56.7)0.96 (0.48-1.93)0.9000.96 (0.48-1.95)0.917
Others12/117 (7.41)/(43.3)5/153 (3.08)/(56.7)0.32 (0.11-0.93)0.0360.32 (0.11-0.94)0.039
Clinical stages
I23/117 (14.2)/(43.3)25/153 (15.4)/(56.7)0.83 (0.45-1.54)0.5560.86 (0.46-1.61)0.645
II15/117 (9.26)/(43.3)7/153 (4.32)/(56.7)0.36 (0.14-0.90)0.0300.35 (0.14-0.89)0.027
III34/117 (21.0)/(43.3)20/153 (12.3)/(56.7)0.45 (0.25-0.82)0.0090.45 (0.25-0.83)0.010
IV28/117 (17.3)/(43.3)9/153 (5.55)/(56.7)0.25 (0.11-0.54)0.00050.26 (0.12-0.60)0.001
4s0/117 (0.00)/(43.3)1/153 (0.006)/(56.7)
I+II+4s38/117 (23.4)/(43.3)32/153 (19.7)/(56.7)0.64 (0.38-1.09)0.1030.65 (0.38-1.10)0.110
III+IV62/117 (38.3)/(43.3)29/153 (17.9)/(56.7)0.36 (0.22-0.59)<0.00010.38 (0.23-0.63)0.0002

OR: odds ratio; CI: confidence interval; AOR: adjusted odds ratio.aAdjusted for age and gender, omitting the corresponding stratify factor.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.